FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatideEli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate Share XTrial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatidehttps://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/
Lilly surges on positive phase 3 readout from diabetes contenderEli Lilly’s decision to throw large amounts of research dollars at its next-generation diabetes drug tirzepatide could be Share XLilly surges on positive phase 3 readout from diabetes contenderhttps://pharmaphorum.com/news/lilly-surges-on-positive-phase-3-readout-from-diabetes-contender/
